Total
0
Shares
SomnoMed (ASX:SOM) - CEO, Neil Verdal-Austin
CEO, Neil Verdal
Sourced: CEO Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • SomnoMed (SOM), a company working in diagnostics and treatment for sleep disorders, has completed the second stage of a $15.5 million capital raising
  • The company has now completed the retail component of its entitlement offer, securing $5.8 million
  • It followed an institutional component which raised $9.7 million
  • SomnoMed has operations in 28 countries and, to varying degrees, all of which has been impacted by COVID-19
  • Due to the unknown duration of those disruptions, the Board decided to undertake the capital raising
  • SomnoMed shares gained 16.3 per cent by market close to be worth $1.32 each

SomnoMed (SOM), a company working in diagnostics and treatment for sleep disorders, has completed the second stage of a $15.5 million capital raising.

The company has now completed the retail component of its fully underwritten entitlement offer, securing $5.8 million. Under the one for 3.24 pro-rata entitlement offer, shares were issued at a price of 80 cents per new share.

Eligible retail shareholders took up 5.4 million shares while the remaining 1.9 million shares will be allocated to sub-underwriters.

The first component of the entitlement offer was the institutional component which raised $9.7 million.

SomnoMed has operations in 28 countries and, to varying degrees, they have all been impacted by COVID-19 according to Chairman Dr Peter Neustadt.

“Many of our medical and dental practices are subject to lockdowns or held to commitments to use their facilities and staff only for the diagnosis and treatment of COVID19 patients or conditions of high urgency.”

“It is impossible to predict the length, the depth and the extent of this crisis. However, we have to assume that it will take months before we see this crisis abating and life returning to some normality.”

Due to the unknown duration of these disruptions, the Board decided to undertake the capital raising to secure the lerm-term future of the company.

Further measures have also been put in place to reduce expenditure, including forgoing director fees and reducing staff and executive pay.

SomnoMed shares gained 16.3 per cent by market close to be worth $1.32 each

SOM by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.